Skip to main content

Camiña Rodríguez, Gabriel Ig

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Camiña Rodríguez, Gabriel Ig

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, SGR-Cat 2021: Neuroimmunologia Clínica, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

IP: Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)
Collaborators: Carlos Nos Llopis, Gabriel Ig Camiña Rodríguez, Ana Zabalza de Torres, Luciana Midaglia Fernandez
Funding agency: The Innovative Medicines Initiative
Funding: 552235
Reference: RADAR_IMI2015
Duration: 01/04/2016 - 31/03/2022

Related news

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

Related professionals

Josep Castellví Vives

Josep Castellví Vives

Senior researcher
Translational Molecular Pathology
Read more
Miquel Raspall Chaure

Miquel Raspall Chaure

Predoctoral researcher
Pediatric Neurology
Read more
Constantino Sábado Álvarez

Constantino Sábado Álvarez

Childhood Cancer and Blood Disorders
Read more
Monica Higuera Urbano

Monica Higuera Urbano

Senior researcher
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.